Severe fluoropyrimidine-related toxicity: Clinical implications of DPYD analysis and UH2/U ratio evaluation

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 5, 2011, Pages 1355-1361

  Giorgio, E ^a   Caroti, C ^a   Mattioli, F ^b   Uliana, V ^a   Parodi, M I ^a   D'Amico, Mauro ^a   Fucile, C ^b   Marini, V ^b   Forzano, F ^a   Cassola, G ^a   Martelli, A ^b   Faravelli, F ^a   Di Maria, E ^a,c  

^a GALLIERA HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

5 FU; Capecitabine; DPYD; UH2 U ratio

Indexed keywords

CA 15-3 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; DIHYDROPYRIMIDINE DEHYDROGENASE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TRASTUZUMAB;

ADULT; AMPLICON; ANALYTICAL PARAMETERS; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CARCINOMA; BREAST DUCTAL CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DIHYDROPYRIMIDINE DEHYDROGENASE GENE; DIHYDROURACIL URACIL RATIO; EXON; FEBRILE NEUTROPENIA; FEMALE; GENE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INTRON; LIVER BIOPSY; LIVER METASTASIS; LOW DRUG DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NAUSEA AND VOMITING; NEEDLE BIOPSY; NEUTROPENIA; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC AGENTS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; HUMANS; MIDDLE AGED; PYRIMIDINES; URACIL;

EID: 82455199207     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1709-6     Document Type: Article

References (21)

1. AB van Kuilenburg 2004 Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil Eur J Cancer 40 7 939 950 15093568 10.1016/j.ejca.2003.12.004 (Pubitemid 38496249)
2. M Tsalic G Bar-Sela A Beny, et al. 2003 Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients Am J Clin Oncol 26 1 103 106 12576935 1:CAS:528:DC%2BD3sXnsFCks7k%3D (Pubitemid 36205907)
3. J Ciccolini C Mercier L Dahan, et al. 2006 Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency Cancer Chemother Pharmacol 58 2 272 275 16292536 10.1007/s00280-005-0139-8 1:CAS:528:DC%2BD28XjvFGitrw%3D
4. R Largillier MC Etienne-Grimaldi JL Formento, et al. 2006 Pharmacogenetics of capecitabine in advanced breast cancer patients Clin Cancer Res 12 18 5496 5502 17000685 10.1158/1078-0432.CCR-06-0320 1:CAS:528: DC%2BD28XpvFShsbY%3D (Pubitemid 44497266)
5. G Bocci C Barbara F Vannozzi, et al. 2006 A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity Clin Pharmacol Ther 80 4 384 395 17015056 10.1016/j.clpt.2006.06.007 1:CAS:528:DC%2BD28XhtVWqurjI (Pubitemid 44479748)
6. G Remaud M Boisdron-Celle C Hameline, et al. 2005 An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice J Chromatogr B Analyt Technol Biomed Life Sci 823 2 98 107 16027050 10.1016/j.jchromb.2005.05.044 1:CAS:528:DC%2BD2MXns1Wnt7s%3D (Pubitemid 41116751)
7. AB van Kuilenburg P Vreken NG Abeling, et al. 1999 Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency Hum Genet 104 1 1 9 10071185 10.1007/PL00008711 (Pubitemid 29134634)
8. R Ben Fredj E Gross AS Ben, et al. 2009 The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil Pathol Biol (Paris) 57 6 470 476 10.1016/j.patbio.2008.05.001 1:CAS:528:DC%2BD1MXhtFagurzP
9. M Boisdron-Celle G Remaud S Traore, et al. 2007 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency Cancer Lett 249 2 271 282 17064846 10.1016/j.canlet.2006.09.006 1:CAS:528:DC%2BD2sXjsVekur8%3D (Pubitemid 46452935)
10. E Gamelin M Boisdron-Celle V Guerin-Meyer, et al. 1999 Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage J Clin Oncol 17 4 1105 10561167 1:CAS:528:DyaK1MXisFentb0%3D
11. H Zhang YM Li X Jin 2007 DPYD 5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients Med Oncol 24 2 251 258 17848752 10.1007/BF02698048 1:CAS:528:DC%2BD2sXpsVKlsLs%3D (Pubitemid 350135979)
12. U Amstutz S Farese S Aebi, et al. 2009 Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment Pharmacogenomics 10 6 931 944 19530960 10.2217/pgs.09.28 1:CAS:528: DC%2BD1MXnsVOkurw%3D
13. K Seck S Riemer R Kates, et al. 2005 Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals Clin Cancer Res 11 16 5886 5892 16115930 10.1158/1078-0432.CCR-04-1784 1:CAS:528: DC%2BD2MXos1Cjurg%3D (Pubitemid 41170317)
14. J Abraham HM Earl PD Pharoah, et al. 2006 Pharmacogenetics of cancer chemotherapy Biochim Biophys Acta 1766 2 168 183 17141416 1:CAS:528: DC%2BD28Xht12rtrjL
15. C Mercier C Dupuis A Blesius, et al. 2009 Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile Cancer Chemother Pharmacol 63 6 1177 1180 19107485 10.1007/s00280-008-0889-1
16. J Ciccolini C Mercier MF Blachon, et al. 2004 A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity J Clin Pharm Ther 29 4 307 315 15271097 10.1111/j.1365-2710.2004.00569.x 1:CAS:528:DC%2BD2cXntFGltbg%3D (Pubitemid 39062160)
17. R Deporte M Amiand A Moreau, et al. 2006 High-performance liquid chromatographic assay with UV detection for measurement of dihydrouracil/uracil ratio in plasma J Chromatogr B Analyt Technol Biomed Life Sci 834 1-2 170 177 16545990 1:CAS:528:DC%2BD28XjsFOgtrw%3D
18. H Ezzeldin Y Okamoto MR Johnson, et al. 2002 A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency Anal Biochem 306 1 63 73 12069415 10.1006/abio.2002.5666 1:CAS:528:DC%2BD38XksFOnsrw%3D (Pubitemid 34722017)
19. Z Kleibl J Fidlerova P Kleiblova, et al. 2009 Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy Neoplasma 56 4 303 316 19473056 10.4149/neo-2009-04-303 1:CAS:528:DC%2BD1MXhsFKjtr3M
20. E Gross B Busse M Riemenschneider, et al. 2008 Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients PLoS ONE 3 12 e4003 19104657 10.1371/journal.pone.0004003
21. E Gross T Ullrich K Seck, et al. 2003 Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects Hum Mutat 22 6 498 14635116 10.1002/humu.9201